All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (never) stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mNSCLC - L1 - all population, immune chekpoint inhibitors vs. placebo plus SoC, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ORIENT-11, 2020 0.61 [0.40; 0.93]
0.61 [0.40 ; 0.93 ] ORIENT-11, 2020 1 0% 397 NA not evaluable progression or deaths (PFS)detailed results ORIENT-11, 2020 0.48 [0.36; 0.64]
0.48 [0.36 ; 0.64 ] ORIENT-11, 2020 1 0% 397 NA not evaluable objective responses (ORR)detailed results ORIENT-11, 2020 2.54 [1.63; 3.97]
2.54 [1.63 ; 3.97 ] ORIENT-11, 2020 1 0% 397 NA not evaluable AE (any grade)detailed results ORIENT-11, 2020 1.02 [0.03; 30.46]
1.02 [0.03 ; 30.46 ] ORIENT-11, 2020 1 0% 397 NA not evaluable AE (grade 3-4)detailed results ORIENT-11, 2020 1.13 [0.74; 1.73]
1.13 [0.74 ; 1.73 ] ORIENT-11, 2020 1 0% 397 NA not evaluable AE leading to death (grade 5)detailed results ORIENT-11, 2020 0.31 [0.11; 0.90]
0.31 [0.11 ; 0.90 ] ORIENT-11, 2020 1 0% 397 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results ORIENT-11, 2020 0.70 [0.31; 1.55]
0.70 [0.31 ; 1.55 ] ORIENT-11, 2020 1 0% 397 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results ORIENT-11, 2020 0.64 [0.26; 1.56]
0.64 [0.26 ; 1.56 ] ORIENT-11, 2020 1 0% 397 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results ORIENT-11, 2020 0.49 [0.01; 24.91]
0.49 [0.01 ; 24.91 ] ORIENT-11, 2020 1 0% 397 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results ORIENT-11, 2020 0.49 [0.01; 24.91]
0.49 [0.01 ; 24.91 ] ORIENT-11, 2020 1 0% 397 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results ORIENT-11, 2020 0.49 [0.01; 24.91]
0.49 [0.01 ; 24.91 ] ORIENT-11, 2020 1 0% 397 NA not evaluable Increase AST TRAE (grade 3-4)detailed results ORIENT-11, 2020 0.49 [0.01; 24.91]
0.49 [0.01 ; 24.91 ] ORIENT-11, 2020 1 0% 397 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results ORIENT-11, 2020 0.49 [0.01; 24.91]
0.49 [0.01 ; 24.91 ] ORIENT-11, 2020 1 0% 397 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results ORIENT-11, 2020 0.98 [0.09; 10.96]
0.98 [0.09 ; 10.96 ] ORIENT-11, 2020 1 0% 397 NA not evaluable Pruritus TRAE (grade 3-4)detailed results ORIENT-11, 2020 0.49 [0.01; 24.91]
0.49 [0.01 ; 24.91 ] ORIENT-11, 2020 1 0% 397 NA not evaluable Rash TRAE (grade 3-4)detailed results ORIENT-11, 2020 0.16 [0.02; 1.56]
0.16 [0.02 ; 1.56 ] ORIENT-11, 2020 1 0% 397 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 19:06 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 36
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743